Drug Trial Radar · NCT01820559
Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine
Last checked: Nov 20, 2026Latest source record: May 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
452
Actual
Start
Apr 2009
Primary completion
Jun 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multinational, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of multiple doses of ESL as prophylactic treatment in subjects with migraine with or without aura. Subjects were randomised in a 1:1:1 ratio to receive placebo, ESL 800 mg/day once daily (QD), or ESL 1200 mg/day QD.
Conditions
- Migraine
Interventions
PlaceboDrug
Tablets
ESL 1200 mgDrug
Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
ESL 800 mgDrug
Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in the Frequency of Migraine AttacksTime frame: 4 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.